SCHEMBL5875865

SCHEMBL5875865

CN(C)CCn1c(=O)c2cccc([N+](=O)[O-])c2c2cnc3cc4c(cc3c21)OCO4

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TDP1 Q9NUW8 7/20 0.47
TOP1 P11387 1/20 0.41
LMNA P02545 2/20 0.41
JAK2 O60674 2/20 0.40
JAK1 P23458 2/20 0.40
TYK2 P29597 2/20 0.40
JAK3 P52333 2/20 0.40
ALDH1A1 P00352 3/20 0.38
MEN1 O00255 2/20 0.37
PABPC1 P11940 2/20 0.37
KMT2A Q03164 2/20 0.37
SMN1; SMN2 Q16637 2/20 0.37
POLB P06746 1/20 0.37
CCR6 P51684 1/20 0.37
NPSR1 Q6W5P4 1/20 0.37
CHRM2 P08172 1/20 0.35
CHRM1 P11229 1/20 0.35
DRD2 P14416 1/20 0.35
ADRA2B P18089 1/20 0.35
ADRA2C P18825 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5875875 0.86 TDP1 (0.50) TDP1TOP1LMNAJAK2JAK1
SCHEMBL5875907 0.83 TDP1 (0.52) TDP1TOP1JAK2JAK1TYK2
SCHEMBL5875889 0.82 JAK2 (0.53) TDP1TOP1LMNAJAK2JAK1
SCHEMBL5875739 0.82 JAK2 (0.57) TDP1TOP1LMNAJAK2JAK1
SCHEMBL2757213 0.78 TDP1 (0.53) TDP1TOP1JAK2JAK1TYK2
SCHEMBL5875897 0.77 TDP1 (0.53) TDP1TOP1JAK2JAK1TYK2
SCHEMBL5875791 0.77 TDP1 (0.53) TDP1TOP1JAK2JAK1TYK2
SCHEMBL29360706 0.75 TDP1 (0.69) TDP1TOP1JAK2JAK1TYK2
SCHEMBL241242 0.75 TDP1 (0.69) TDP1TOP1JAK2JAK1TYK2
SCHEMBL12457094 0.75 TDP1 (0.56) TDP1TOP1JAK2JAK1TYK2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6989387-B2 Nitro and amino substituted topoisomerase agents RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY (US) 2006-01-24 US disclosed
US-20040110760-A1 Nitro and amino substituted topoisomerase agents RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY 2004-06-10 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040110760-A1 Nitro and amino substituted topoisomerase agents TOP1, TOP2A, TOP2B TDP1 4/4885TOP1 1/4885LMNA 1178/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.